

Hepatocyte growth factor, its receptor, and their potential value in cancer therapies

Wen G. Jiang^{a,*}, Tracey A. Martin^a, Christian Parr^a, Gaynor Davies^a,
Kunio Matsumoto^b, Toshikazu Nakamura^b

^a *Metastasis and Angiogenesis Research Group, University Department of Surgery, Wales College of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK*

^b *Division of Molecular Regenerative Medicine, Course of Advanced Medicine, Osaka University Graduate School of Medicine, Osaka, Suita, Japan*

Accepted 14 September 2004

Contents

1. Molecular signalling of the HGF/cMET complex	37
1.1. HGF induces motility and migration of cancer cells	37
1.1.1. The rho/rac pathway	37
1.1.2. The PI3K pathway	38
1.1.3. The FAX/paxillin pathway	38
1.1.4. The ERM connection	38
1.1.5. Other pathways linked to motility	39
1.2. The disruption of cell–cell adhesion complex, the β -catenin connection	39
1.3. The growth/death pathways	39
1.4. A special case in cell growth and motility regulation?	40
1.4.1. A new clue in migration/growth separation and connection	40
1.4.2. Growth inhibitor and stimulus, a hidden myth	41
1.5. HGF promotes invasiveness of cancer cells	41
1.6. HGF is a powerful angiogenic factor	41

Abbreviations: Abl, Abelson murine leukemia viral oncogene; AGTR, angiotensin II receptor; Arf, Archaeal Rieske-type ferredoxin; Arp, actin-related protein; BCL2, B-cell CLL/lymphoma 2; BID, BH3 interacting domain death agonist; cMET, receptor for hepatocyte growth factor; CDK, cyclin-dependent kinase; CMT, Chemically modified tetracycline; COX-2, cyclooxygenase-2; Creb, cAMP responsive element binding protein; Crk, Avian sarcoma virus CT10 oncogene; Crkl, CRK like protein; CTGF, connective tissue growth factor; ECM, extracellular matrix; Edg, endothelial differentiation gene; EGFR, epidermal growth factor receptor; EMT, epithelial–mesenchymal transition; EPA, eicosapentaenoic acid; ERM, ezrin/radixin/moesin family protein; Fadd, Fas (TNFRSF6)-associated via death domain; FAK, focal adhesion kinase; FGF, fibroblast growth factor; Flk, protein tyrosine kinase acting as VEGF receptor; GAB, GRB2-associated binding protein (GAB); GDI, guanine nucleotide dissociation inhibitor; GLA, gamma linolenic acid; GRB, growth factor receptor-bound protein (SH2/SH3 domain adapter protein); GSK3 β , glycogen synthase kinase 3 beta; HA, hyaluronic acid; HAI, Hepatocyte growth factor activator inhibitor; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; HGFA, hepatocyte growth factor activator; HIF, hypoxia-inducible factor; HS, Heparan sulphate; Hsp, heat shock protein; HUVEC, human umbilical vein endothelial cells; ICAM, intercellular adhesion molecule; IGFR, insulin-like growth factor receptor; LIMK, LIM kinases that have over 40 members; MAPK, mitogen activated protein kinase; MEK, MAP kinase kinase; MIMP, Met-induced mitochondrial protein; MMP, metalloproteinase; NK4, N-termus and four kringle domain of HGF; OPN, osteopontin; PAK, p21(CDKN1A)-activated kinase; PAR, protease activated receptor; PG, prostaglandin; PI3K, phosphatidylinositol 3-kinase; PLC, phospholipase C; PPAR, peroxisome proliferative activated receptor; RA, retinoic acid; raf-1, leukemia viral oncogene 1; Ras, rat sarcoma virus oncogene; RCC, renal cell carcinoma; Rb-1, retinoblastoma 1; Rho, ras homolog gene family; Rock, Rho-associated; coiled-coil containing protein kinase; RyR, ryanodine receptor; Shc1, src homology 2 domain-containing transforming protein C1; SF, scatter factor; Src, v-src sarcoma (Schmidt–Ruppin A-2) viral oncogene homolog; SRE, serum response element; STAT, signal transducer and activator of transcription; TCF-1, transcription factor-1; TEM, specific tumour endothelial marker; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; Trk, potassium uptake system protein; TSP1, thrombospondin 1; uPA, urokinase plasminogen activator; VEGF, vascular endothelial growth factor; VHL, von Hippel–Lindau protein; WASP, Wiskott–Aldrich syndrome protein; WAVE, WAS protein family member; Wnt, wingless-type MMTV integration site family

* Corresponding author. Tel.: +44 29 2074 2895; fax: +44 29 2076 1623.

E-mail address: jiangw@cf.ac.uk (W.G. Jiang).

1.7.	HGF is a morphogenesis factor	42
1.8.	HGF disrupts cellular structures such as tight junctions and adherens junctions	42
1.9.	Interaction of HGF/cMET complex with other complexes	42
2.	Source and storage of HGF in vitro and in vivo	42
2.1.	Source of HGF	42
2.2.	HGF regulators	44
3.	HGF and its role in cancer development, the clinical aspect	46
3.1.	HGF and carcinogenesis	47
3.2.	Prognostic value	48
4.	HGF, cMET and therapeutic opportunities	48
4.1.	HGF antagonist, NK4	48
4.1.1.	Structure of NK4	48
4.1.2.	Lung cancer model	49
4.1.3.	Ovarian cancer model	49
4.1.4.	Gastric cancer model	49
4.1.5.	Gliomas	49
4.1.6.	Haematological malignancies	49
4.1.7.	Pancreatic tumour mode	49
4.1.8.	Breast tumour model	50
4.1.9.	Colorectal cancer	50
4.1.10.	Prostate cancer	51
4.2.	Anti-met and anti-signalling small compounds	51
4.2.1.	cMET kinase inhibitors	51
4.2.2.	Rock inhibitors	52
4.2.3.	Inhibitors to other kinases	53
4.3.	Matrix degradation inhibitors	54
4.4.	Anti-HGF antibodies	54
4.5.	Lipid and lipid metabolism inhibitors	54
4.5.1.	Unsaturated fatty acids	54
4.5.2.	Lipid converting enzymes	54
4.6.	Agents related to anti-angiogenesis	55
4.7.	Ribozymes and genetic approach	55
4.8.	HGF activation inhibitors	55
4.9.	Cytokines	56
4.10.	Manipulating tumour-related genes	57
4.11.	The matrix connection	57
4.12.	Agents counteracting HGF-induced cellular changes	57
4.13.	Chemically modified tetracyclines (CMT)	57
4.14.	Sphingosine 1-phosphate	58
4.15.	Other compounds	58
4.16.	Hormone related	58
4.17.	Other approaches	58
5.	Pre-clinical and clinical studies	58
5.1.	HGF as indicator of prognosis and markers for therapies	58
5.2.	Manipulation HGF and possible implication in chemo- and radio-therapy	59
6.	The prospective future in anti-HGF/cMET therapies	59
	Reviewers	60
	References	60
	Biographies	68

Abstract

Hepatocyte growth factor plays multiple roles in cancer, by acting as a motility and invasion stimulating factor, promoting metastasis and tumour growth. Furthermore, it acts as a powerful angiogenic factor. The pivotal role of this factor in cancer has indicated HGF as being a potential target in cancer therapies. The past few years have seen rapid progress in developing tools in targeting HGF, in the context of cancer therapies, including development of antagonists, small compounds, antibodies and genetic approaches. The current article discusses the potential value of HGF and its receptor as targets in cancer therapies, the current development in anti-HGF research, and the clinical value of HGF in prognosis and treatment.

©2004 Elsevier Ireland Ltd. All rights reserved.

Keywords: Hepatocyte growth factor; HGF; cMET; Cancer metastasis; Angiogenesis; Signal transduction; Cancer therapies

Download English Version:

<https://daneshyari.com/en/article/9257636>

Download Persian Version:

<https://daneshyari.com/article/9257636>

[Daneshyari.com](https://daneshyari.com)